In an interview, Héctor Vera Cuesta, director of the International Center for Neurological Restoration (CIREN, in Spanish) on a visit to Mexico, told La Jornada about the progress in treating patients based on a molecule that prevents neurons from continuing to degeneration process.
It is a substance called NeuroEPO, which improves patients´ quality of life. Cuesta explained such a molecule´s mechanism is neuroprotective. It prevents neurons from degenerating further.
Cuesta, a Cuban neurologist and expert in medical genetics, claimed these results in patients with Parkinson’s and Alzheimer’s have been staggering.
The study began to be conducted in patients with Parkinson’s, founding such a substance improved its motor condition, but much more the cognitive one.
It is one of the molecules that is going to give the world something to talk about. We recently published a joint article with the Cuban Neuroscience Center, confirming with a well-developed statistical analysis that it is quite effective.
Vera Cuesta announced that NeuroEPO will soon be commercialized. We want to do a phase IV (of the clinical study), because every new molecule has a rigorous research process. At this stage we want to apply it massively.
The Cuban scientists are currently identifying hospitals where the study will be conducted, since “it does not have side effects. It is safe and too easy to administer, nasal administration”.
pll/jcm/lma
